Amgen Netherlands

Amgen Oncology

Amgen France

Amgen Deutschland

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

See our Community Guidelines: bit.ly/smcgl
See our Global Privacy Statement Directory: www.amgen.com/dp

Special Advisory: Please be cautious of scam recruitment offers claiming to be from Amgen. Such scams may come from various sources, including fake websites and/or unsolicited emails and seek to obtain personal data or payment from victims by offering jobs that do not exist. Please be advised that Amgen would never ask for payment to progress a job application. When in doubt, please check to see if the position in question is posted on this website before applying. Additionally, please report any suspicious recruiting activity to https://complaint.ic3.gov/ and thank you for your assistance.

SomaLogic

Unilife Corporation

Science 37

BeiGene

immatics biotechnologies

Jasper Therapeutics

Oxford Nanopore Technologies

Amgen

See what’s happening at our second-largest research and development facility: Amgen San Francisco.

Thanks to Jason DeVoss for the exclusive tour. 

At Amgen, we join forces with the healthcare community to unlock innovative therapies, giving cancer patients the chance to look ahead with renewed optimism. Together, we fight for a brighter future. 
#AmgenHellas #WorldCancerDay

Amgen's P. Ryan Potts, Ph.D. is the featured scientist on the latest episode of People Behind The Science: https://amgen.ly/493gEGi

🎧 Tune in to hear him talk about his career journey, hobbies, his battle with pediatric cancer that led him to science and all the exciting work the Amgen R&D team is now doing around multispecifics and proximity-based therapeutics. 

What leadership qualities reflect our mission to serve patients? That’s what our R&D team asks each year when it’s time to nominate their leaders of the year. This tradition is an opportunity to celebrate exemplary leadership in R&D who advance an organization-wide culture of best-in-class leadership! Learn more about our collaborative culture: https://bit.ly/3GYzpOX

🔊 Tune into the latest episode of the National Association of Specialty Pharmacy (NASP) podcast featuring Amgen's Bethany Kalich, PharmD: https://amgen.ly/3uqJzVQ  

In this insightful session, Bethany discusses the vital role pharmacists and healthcare agencies play in reducing gender disparities in cardiovascular health. Amgen is actively committed to addressing cardiovascular inequities to enhance women's heart health. 

Repatha

Vecta

Mi Momento

GOtezla – Amgen, Inc.

IgniteChange

OBI Digital Companion

ESA APPRISE

Amgen Medical Information

GDnA-Genie

Neutropenie.de

Viewport Meta

IPhone / Mobile Compatible

Domain Not Resolving

SSL by Default

Google Tag Manager

Apple Mobile Web Clips Icon

HSTS

Google Font API

DNSSEC

Content Delivery Network

Associate General Counsel

Allan Dinkoff

Windows System Engineer/ Application System Owner

Althaf Ahamed

Senior Marketing Executive - Cardiology & Renal

Alyson Kilbride

Master Data Management / Equipment System Ownership

Andrew Midelka

Associate General Counsel, Transactions

Andrew Turney

Upstream Process Owner

Brianne Guglielmo

Process Owner

Bryant Almazan

Global Chairman, Amgen Latin Employee Network

Carlos Cojulun

Manufacturing Specialist

Carly Ferias

Combination Product Design Control Business Process Owner (BPO)

Ceylan Guclu

Fred Hassan

David Baltimore

Frank Herringer

Tyler Jacks

Robert Williams

Ronald Sugar

Robert Eckert

Judith C. Pelham

Esteban Santos

Executive Vice President, Operations

Howard Chang

SVP of Research

Rizwan Sharnez

Scientific Director

Teresa Johnson

Global Strategic Sourcing Category Senior Manager

Alexander Kamb

Senior Vice President, Discovery Research

David Haddad

Director of Product Management

Tom Mistretta

Director Data Science

Nadene McIntyre

Director

Oxford Nanopore Technologies is a biotechnology company that develops and commercializes nanopore sequencing technology.

Science 37 is a clinical research company that facilitates universal participation in clinical trials for patients and providers.

Jasper Therapeutics is a biotechnology company that develops novel antibody therapies for stem cell transplants.

SomaLogic is a protein biomarker discovery and clinical diagnostics company, offers SOMAmer technology to improve diagnostic products.

Immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy.

Neumora Therapeutics operates as a clinical-stage biotechnology company.

Unilife is a U.S-based medical device and technology company that designs, develops, manufactures and supplies innovative.

Manufacturing Public Companies With More Than $1M in Revenue

Biotechnology Public Companies With More Than 500 Employees

Investors Active in Oxfordshire

Western US Companies With More Than $1M in Revenue (Top 10K)

Amgen is a biotechnology company that develops and manufactures human therapeutics for various illnesses and diseases. The company is values-based and deeply rooted in science and innovation to transform new ideas and discoveries into medicines for patients with serious diseases. They offer products for treating illness in the areas of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience.

Post-IPO Debt - Amgen

Thousand Oaks

California

United States

North America

AMGEN ANNOUNCES SENIOR EXECUTIVE RESEARCH APPOINTMENT

ETF of the week: Focus on the American old guard

Amgen Names Howard Chang as Chief Scientific Officer

Specialty Pharmaceuticals Research Report: Increased Reimbursement Through Medical and Pharmacy Benefits Driving the Market, Reaching $965 Billion by 2030

Dow Tumbles Over 300 Points Following Economic Reports, Nvidia, Microsoft Decline: Fear & Greed Index Moves To 'Neutral' Zone

Plaque Psoriasis Research Report 2024: 7 Major Market and 61 Additional Country Market Analysis and Sales Forecasts 2020-2030

Neurogene, Nvidia And Other Big Stocks Moving Lower In Monday's Pre-Market Session

AMGEN ALERT: Bragar Eagel & Squire, P.C. is Investigating Amgen Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

US stocks continue decline on rate cut pause prospects

Drug markets uneasy about RFK Jr.

Amgen develops biosimilar medicines that are highly similar to existing biologic drugs, focusing on oncology, hematology, and chronic inflammatory diseases.

Amgen is involved in developing therapies targeting cancer, including precision oncology and targeted immunotherapy approaches.

A global initiative providing hands-on biotechnology education to secondary school students, offering professional-grade scientific equipment and training.

The philanthropic arm of Amgen, supporting science education and community initiatives through grants and donations.

India

Asia

Puerto Rico

Germany

Europe

Singapore

HTML5

.NET 4.5

Bootstrap

Adobe Flash

Wordpress

jQuery

Akamai Intelligent Platform

Google Drive

Google Analytics

Office 365

Amgen owns Onyx Pharmaceuticals

Amgen owns Immunex

Amgen owns Amgen Ventures

Eli Lilly and Company is a global pharmaceutical company that develops and markets human pharmaceuticals and animal health products.

Eli Lilly and Company

AbbVie is a research-based biopharmaceutical company that develops and markets advanced therapies for a wide range of diseases.

AbbVie Inc.

Pfizer is a multinational pharmaceutical company that develops and produces medicines and vaccines for a wide range of medical disciplines.

Pfizer Inc.

There are numerous other competitors in the biopharmaceutical industry, including both established companies and emerging biotech firms.

Various other competitors

Amgen Inc. is an American multinational biopharmaceutical company committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. It focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives.

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas. The company's products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta that reduces the chance of infection due a low white blood cell count in patients cancer; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Aranesp to treat a lower-than-normal number of red blood cells and anemia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; and Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization. It also markets Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. Amgen Inc. serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. It has collaboration agreements with Novartis Pharma AG; UCB; Bayer HealthCare LLC; BeiGene, Ltd.; Eli Lilly and Company; Datos Health; and Verastem, Inc. to evaluate VS-6766 in combination with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. It has an agreement with Kyowa Kirin Co., Ltd. to jointly develop and commercialize KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody for the treatment of atopic dermatitis and other autoimmune diseases; and research and development collaboration with Neumora Therapeutics, Inc. and Plexium, Inc. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.

news impact assignment basic	general	Mar 7, 2024 3:10 PM	dd14abe9
public peers	general
news daily refresh	general	Dec 4, 2024 2:16 PM	2973f602
news processing daily refresh	general	May 21, 2024 2:58 AM	561a3d04
news impact assignment daily	general	May 21, 2024 4:58 PM	3e0e3d35
news processing basic	general	Mar 7, 2024 3:10 PM	9f0f386e
company summary	general
signals	general	Mar 7, 2024 3:10 PM	0aea10a5
crunchbase trigger	general	Nov 25, 2024 9:06 AM	0fb93e6c
crunchbase profile	general	Nov 25, 2024 11:37 AM	5ca863d6
li profile	general	Mar 7, 2024 3:10 PM	a92aed8e
translate crunchbase fundingrounds	general	Nov 25, 2024 2:13 PM	72a7b848
peers	general	Mar 7, 2024 3:10 PM	9a79043e
news basic	general	Dec 4, 2024 2:13 PM	e2dee77a
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:AMGEN

Amgen Inc.

Last Close

289.90

22/11 21:00

Market Cap

172.56B

Beta: -

Volume Today

3.05M

Avg: -